USE OF MIRNA-485 INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)

• Main Authors: KIM Dae Hoon, RYU Jin-hyeob, LIM Yu Na, MIN Hyun Su, KOH Han Seok
• Format: Patent
• Language: English; Spanish
• Published: 31.10.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present disclosure includes the use of a miRNA inhibitor for treating amyotrophic lateral sclerosis (ALS) associated with a decreased level of SIRT1 protein or SIRT1 gene expression, PGC-1α protein and/or PGC-1α gene expression, CD36 protein and/or CD36 gene expression, NRG1 protein and/or NRG1 gene expression, STMN2 protein and/or STMN2 gene expression, and/or NRXN1 protein and/or NRXN1 gene expression. La presente descripción incluye el uso de un inhibidor de miARN para el tratamiento de la esclerosis lateral amiotrófica (ELA) asociada con un nivel disminuido de expresión de proteína SIRT1 o del gen SIRT1, expresión de proteína PGC-1a y/o del gen PGC-1a, expresión de proteína CD36 y/o del gen CD36, expresión de proteína NRG1 y/o del gen NRG1, expresión de proteína STMN2 y/o del gen STMN2 y/o expresión de proteína NRXN1 y/o del gen NRXN1.